{"disease":{"id":"primary-autoimmune-hemolytic-anemia","name":"primary autoimmune hemolytic anemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07039422","title":"Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05057468","title":"Second-line Treatment of Primary Autoimmune Hemolytic Anemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06888960","title":"Safety Study of CC312 in Autoimmune Disease Patients","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"CytoCares Inc","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}